Scinai Ends PC111 Deal, Redirects Capital to NanoAb Platform and CDMO Growth
核心洞察
Scinai Immunotherapeutics (搜索) allowed its option and license agreements with PinCell (搜索) for the preclinical PC111 program to expire on August 31, 2026, citing capital-allocation priorities rather than negative scientific data.
The company is redirecting R&D resources to its NanoAb platform, including intradermal and systemic IL-17 (搜索) programs, while maintaining its collaboration with the Max Planck Society (搜索) and University Medical Center Göttingen.
Scinai reported approximately $3.1 million in committed CDMO customer orders as of mid-August and is targeting roughly $5 million in CDMO revenue for 2026.
Scinai Immunotherapeutics (搜索) Ltd. (Nasdaq: SCNI) announced on September 8, 2026 that it has allowed its option and license agreements with PinCell (搜索) S.r.l. relating to the preclinical program PC111 to expire, ending its involvement without securing new funding. The applicable option conditions expired on August 31, 2026, and the Option Agreement and related License Agreement terminated in accordance with their terms. The company emphasized that the decision was not driven by any new negative scientific finding regarding PC111, but rather by capital-allocation priorities.
Amir Reichman, Chief Executive Officer of Scinai, commented: "PC111 remains an interesting and promising preclinical program, and we greatly appreciate our collaboration with Tony Amato and the PinCell (搜索) team. Following the conclusion of our existing arrangements, our responsibility is to determine where Scinai's capital and management resources can create the greatest value for shareholders."
Reichman explained the rationale further: "Advancing any preclinical asset through meaningful de-risking requires substantial capital and time. In the absence of secured grant funding for PC111, continuing our involvement would have required additional investment before there was visibility on non-dilutive financing."
Refocusing on the NanoAb Platform
Scinai is redirecting its R&D resources to its NanoAb platform, which uses VHH antibody fragments to support the development of mono-, bi- and multi-specific therapeutic formats for inflammatory and immune-mediated diseases. The company remains committed to its multi-year research collaboration with the Max Planck Society (搜索) and University Medical Center Göttingen.
Management believes the NanoAb platform provides multiple potential development paths from a common technology base, creating opportunities to generate value across several therapeutic programs and potentially pursue partnering and co-development arrangements with pharmaceutical companies.
Scinai is currently advancing two complementary IL-17 (搜索) programs within the platform. Its intradermal IL-17 program for psoriasis (搜索) is the subject of an application currently under evaluation under Poland's FENG program for approximately €12 million in grant financing, intended to support development from the preclinical stage through first-in-human readiness. An award decision is currently expected following completion of the evaluation process, although the timing and outcome of the grant review remain outside Scinai's control.
In parallel, Scinai's systemic IL-17 (搜索) bispecific program remains an important validation program for the broader NanoAb platform, with in vivo proof-of-concept representing the next major development milestone. The company is also developing a broader portfolio of mono-, bi- and multi-specific NanoAb candidates.
CDMO Commercial Momentum
The portfolio refocusing accompanies commercial progress described in Scinai's August 24, 2026 announcement of its first-half results. As of August 16, 2026, Committed Customer Orders totaled approximately $3.1 million across the Jerusalem and Yavne facilities. The company continues to pursue approximately $5 million of CDMO revenue for 2026, subject to project execution, timing, applicable revenue-recognition criteria and conversion of additional opportunities.
Scinai has commenced substantive activities on a previously disclosed expanded clinical manufacturing and chemistry, manufacturing and controls (CMC) program for a U.S.-based biopharmaceutical customer. The program is intended to support a planned U.S. regulatory submission and subsequent Phase III clinical development, with potential future expansion into commercial manufacturing. Activities are being performed under an existing contractual relationship, while the parties continue to negotiate a definitive agreement covering the broader scope and commercial terms.
The company is also evaluating inquiries for additional projects of comparable scope. Management believes successful execution of larger customer programs, repeat business and improved facility utilization can support progress toward sustainable CDMO profitability and strengthen the group's financial resilience.
"This decision should be viewed in the context of the company we are building," Reichman added. "Our priorities are to advance our focused NanoAb portfolio, deliver for our CDMO customers and convert the capabilities of our two-site platform into revenue and improved operating performance."
Scinai Immunotherapeutics (搜索) is a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization. The company owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.